Dr. Jamie Platt, Vice President of Genomic Solutions at Geneuity and Molecular Pathology Laboratory Network, Inc., evaluated the illumina TruSight® Tumor 15 and said the panel’s simplicity and ease of use makes it well-suited for translational labs, “The value and appeal of next-generation sequencing is the potential to consolidate traditionally iterative tumor analyses. Our evaluation of the new TruSight Tumor 15, with its streamlined library prep and sequencing workflow, gives us confidence that this application is ideal for deployment. Even our most challenging samples produced results, including those with low nucleic acid inputs, giving us assurance we can analyze our most precious specimens.”

Read illumina’s press release on Business Wire

Leave a Reply